Difficulties in selecting specific therapy in severe forms of congenital cytomegalovirus infection: view through time

The aim — to show the feasibility of using ganciclovir for congenital cytomegalovirus infection (CMVI) by demonstrating two clinical cases. Clinical Over time, approaches treatment CMVI have changed from use acyclovir appointment ganciclovir. In 2011, a premature baby was diagnosed with based on presence multiple organ lesions (lungs, liver, spleen, pancreas, eyes, central nervous system) and positive result CMV PCR test in blood, urine cerebrospinal fluid. Only used as an etiotropic drug due lack evidence at that time safety another antiviral Treatment not completely effective: follow;up age child has grave violation hearing vision profound disability residual effects system. 2019, newborn severe haemorrhagic syndrome, respiratory disorders neurological symptoms prescribed dose 6 mg/kg every 12 hours intravenous infusion under control routine complete blood count (CBC) test. On second week treatment, dynamics observed clinically, 6th negative discharged day 70th without At 9 months, deafness 2–3 degrees diagnosed, but prosthetics were performed timely restoration hearing. month this sits, rolls over, crawls; responds adequately others; captures gaze keep eye items. Conclusions. Two cases through description changes specific therapy disease clear demonstration difference outcomes when prescribed, rehabilitation its demonstrate prescribing research carried out accordance principles Helsinki Declaration. informed consent patient obtained conducting studies. No conflict interest declared authors. Key words: infection, forms, acyclovir,